Use of pharmacy data to evaluate smoking regulations' impact on sales of nicotine replacement therapies in New York City

American Journal of Public Health

Volumn 95, Issue 6, 2005, Pages 1050-1055

  Metzger, Kristina B ^a   Mostashari, Farzad ^a   Kerker, Bonnie D ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CIGARETTE SMOKING; DRUG MARKETING; GOVERNMENT REGULATION; HEALTH PROGRAM; LOWEST INCOME GROUP; NICOTINE REPLACEMENT THERAPY; PHARMACY; PREVALENCE; SMOKING CESSATION; TAX; UNITED STATES; WORKPLACE;

HEALTH PROMOTION; HUMANS; NEW YORK CITY; NICOTINE; PHARMACIES; POISSON DISTRIBUTION; PUBLIC POLICY; SMOKING; SMOKING CESSATION; TAXES; TOBACCO INDUSTRY; TOBACCO USE DISORDER; URBAN POPULATION; WORKPLACE;

EID: 19644391933     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.048025     Document Type: Article

References (26)

1. Chaloupka FJ, Warner KE. The economics of smoking. In: Culver AJ, Newhouse JP, eds. Handbook of Health Economics. Vol 1B. Amsterdam, Netherlands: Elsevier; 2000:1539-1627.
2. Fichtenberg CM, Glantz SA, Association of the California tobacco control program with declines in cigarette consumption and mortality from heart disease. N Engl J Med. 2000;343:1772-1777.
3. Reducing Tobacco Use: A Report of the Surgeon General, Atlanta, Ga: National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: 2000.
4. Wilson N, Thomson G. Still dying from second-hand smoke at work: a brief review of the evidence for smoke-free workplaces in New Zealand. N Z Med J. 2002;115:240-249.
5. Fiore MC, Croyle RT, Curry SJ, et al. Preventing 3 million premature deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. Am J Public Health. 2004;94:205-210.
6. Henning KJ. What is syndromic surveillance? MMWR Morb Mortal Wkly Rep. 2004;53(suppl):7-11.
7. Mostashari F, Hartman J. Syndromic surveillance: a local perspective. J Urban Health. 2003;80(suppl 1): i1-i7.
8. Heffernan R, Mostashari F, Das D, Karpati A, Kulldorff M, Weiss D. Syndromic surveillance in public health practice, New York City. Emerg Infect Dis. 2004; 10:585-864.
9. Mostashari F, Fine A, Das D, Adams J, Layton M. Use of ambulance dispatch data as an early warning system for communirywide influenzalike illness, New York City. J Urban Health. 2003;80(suppl 1):i43-i49.
10. Das D, Mostashari F, Weiss D, Balter S, Heffernan R. Monitoring over-the-counter pharmacy sales for early outbreak detection in New York City [abstract]. MMWR Morb Mortal Wkly. 2004;53(suppl):235.
11. Burton SL, Kemper KE, Baxter TA, Shiffman S, Gitchell J, Currence C. Impact of promotion of the Great American Smokeout and availability of over-the-counter nicotine medications, 1996. MMWR Mortal Wkly Rep. 1997;46:867-871.
12. New York City Smoke-Free Air Act, Chapter 5, Title 17 of the New York City Administration Code as amended by Local Law no. 47, 2003.
13. Miller N, Frieden TR, Liu SY, et al. Effectiveness of a large-scale free nicotine patch distribution program. Lancet In press.
14. Norcross JC, Vangarelli DJ. The resolution solution: longitudinal examination of New Year's change attempts. J Subst Abuse. 1989;1:127-134.
15. Walsh RA, Paul CL. New Year quit smoking resolutions. Aust N Z J Public Health. 2002;26:181.
16. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
17. Census 2000 Summary File 3. New York: US Census Bureau; 2001. Available at: http://www.census.gov/prod/cen2000/doc/sf3.pdf. Accessed May 3, 2005.
18. Tauras JA. The Transition to Smoking Cessation: Evidence From Multiple Failure Duration Analysis, Cambridge, Mass: National Bureau of Economic Research; 1999. NBER Working Riper 7412. Available at: http://www.nber.org/ papers/w7412. Accessed February 2, 2004.
19. Moskowitz JM, Lin Z, Hudes ES. The impact of workplace smoking ordinances in California on smoking cessation. Am J Public Health, 2000;90:757-761.
20. Tauras JA, Chaloupka FJ. The demand for nicotine replacement therapies. Nicotine Tub Res. 2003;5: 237-243.
21. Farralley MC, Bray JW. Response to increases in cigarette prices by race/ethnicity, income and age groups-United States, 1976-1993. MMWR Morb Mortal Wkly Rep. 1998;47:605-609.
22. Frieden TR, Mostashari F, Kerker BD, Miller N, Hajat A, Frankel M. Adult tobacco use levels after intensive tobacco control measures: New York City, 2002-2003. Am J Public Health. 2005;95:1016-1023.
23. Shaw JP, Ferry DG, Pethica D, Brenner D, Tucker IG. Usage patterns of transdermal nicotine when purchased as a non-prescription medicine from pharmacies. Tob Control. 1998;7:161-167.
24. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preference for and responses to four nicotine replacement products, Psychopharmacology. 2001;153:225-230.
25. Metzger KB, Hajat A, Crawford M, Mostashari F. How many illnesses does one emergency department visit represent? Use of a population-based telephone survey to estimate the syndromic multiplier. MMWR Morb Mortal Wkly Rep. 2004;53(suppl):106-111.
26. Mostashari F, Kerker BD, Hajat A, Miller N, Frieden TR. Smoking practices in New York City: the use of a population-based survey to guide policy-making and programming. J Urban Health. 2005;82: 58-70.